Elysium Therapeutics

Jun 11, 2025

Elysium Therapeutics' Investor Webcast Highlights "Fentanyl Rebound" as Key Challenge in Reducing Opioid Overdose Hospitalizations and Deaths

May 12, 2025

Elysium Therapeutics to Host Investor Webcast Highlighting SOOPR(TM) Program and the Need to Address "Fentanyl Rebound" as Key Challenge in the Opioid Overdose Epidemic

Apr 07, 2025

Elysium Therapeutics Announces Development of Overdose Rescue Technology Specifically Designed for Oral Fentanyl

Sep 03, 2024

Elysium Therapeutics Presents Phase 1 Proof-of-Concept Results for Novel SMART(TM) O2P Opioid Technology for Acute Pain that Reduces the Potential for Abuse, Diversion, and Risk of Oral Overdose at PAINWeek 2024

Mar 05, 2024

Elysium Therapeutics Announces Compelling Human Proof-of-Concept Data for its SMART(TM) Opioid, O2P(TM) Hydrocodone Prodrug for Acute Pain that Could Disrupt the Industry by Establishing New Standards for Opioid Safety